Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA

Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA

The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III BCD-085-5/ASTERA study.Objective: to evaluate the long-term efficacy and safety of NTK over a three-year period in patients with active AS.Material and meth...

Full description

Saved in:
Bibliographic Details
Main Authors: V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, V. V. Tyrenko, E. A. Mikhailova, A. V. Eremeeva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2024-02-01
Series:Современная ревматология
Subjects:
netakimab
interleukin-17a
monoclonal antibody
ankylosing spondylitis
Online Access:https://mrj.ima-press.net/mrj/article/view/1529
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://mrj.ima-press.net/mrj/article/view/1529

Similar Items